Key result
Cangrelor was successfully used as bridge therapy prior to gastroduodenal biopsy in a woman with a history of gastrointestinal bleeding on DAPT for a drug-eluting stent.
Case Report (n=1)
Cangrelor may be utilized as an antiplatelet bridge therapy for patients on DAPT requiring urgent procedures such as gastroduodenal biopsy.
May support cangrelor bridging in select high-bleeding-risk DAPT cases; leaves open need for prospective validation.
Dual antiplatelet therapy (DAPT) is the key for secondary prevention of acute coronary syndromes and percutaneous coronary intervention with stent placement. Premature discontinuation of DAPT can result in an increase in cardiac ischemic events and death. If early interruption of DAPT for urgent procedures or surgery is necessary, then ischemic and bleed risks must be balanced with bridging therapy. To date, no medications have a Food and Drug Administration indication for antiplatelet bridge therapy. We present a case of a woman with a history of gastrointestinal bleeding on DAPT for a drug-eluting stent who received cangrelor as bridge therapy prior to gastroduodenal biopsy.
No takes yet. Share an insight, caveat, or question.
Cahoon et al. (2016) conducted a case report in History of gastrointestinal bleeding on DAPT for a drug-eluting stent requiring gastroduodenal biopsy (n=1). Cangrelor bridge therapy was evaluated. Cangrelor was successfully used as bridge therapy prior to gastroduodenal biopsy in a woman with a history of gastrointestinal bleeding on DAPT for a drug-eluting stent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: